Seer, Inc.SEEREarnings & Financial Report
Nasdaq
Seer, Inc. is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.
SEER Q3 2025 Key Financial Metrics
Revenue
$4.1M
Gross Profit
$2.1M
Operating Profit
$-19.3M
Net Profit
$-18.2M
Gross Margin
51.2%
Operating Margin
-469.4%
Net Margin
-442.5%
YoY Growth
2.2%
Financial Flow
Seer, Inc. Q3 2025 Financial Summary
Seer, Inc. reported revenue of $4.1M for Q3 2025, with a net profit of $-18.2M (-442.5% margin). Cost of goods sold was $2.0M, operating expenses totaled $21.5M.
Key Financial Metrics
| Total Revenue | $4.1M |
|---|---|
| Net Profit | $-18.2M |
| Gross Margin | 51.2% |
| Operating Margin | -469.4% |
| Report Period | Q3 2025 |
Seer, Inc. Annual Revenue by Year
Seer, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $14.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $14.2M |
| 2023 | $16.7M |
| 2022 | $15.5M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.4M | $3.1M | $3.1M | $4.0M | $4.0M | $4.2M | $4.1M | $4.1M |
| YoY Growth | -3.6% | -24.4% | -23.4% | -3.1% | -9.9% | 37.1% | 31.9% | 2.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $436.3M | $422.0M | $406.6M | $383.4M | $366.6M | $347.3M | $322.5M | $308.6M |
| Liabilities | $39.4M | $38.4M | $41.9M | $38.7M | $39.0M | $36.3M | $34.2M | $36.8M |
| Equity | $396.9M | $383.6M | $364.7M | $344.7M | $327.6M | $311.0M | $288.3M | $271.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.2M | $-10.5M | $-10.1M | $-14.1M | $-11.5M | $-11.4M | $-14.7M | $-7.6M |